周兵

个人信息：

周兵 博士

研究员，国科大杭州高等研究院

浙江省杭州市西湖区象山支路1号 310012

Phone:021-68077803  

E-mail: zhoubing@simm.ac.cn

教育背景：

2000年9月-2004年7月  同济大学 化学工程与工艺 学士  

2004年9月-2007年1月  同济大学  无机化学   硕士

2008年9月-2011年6月  中国科学院上海药物研究所 药物化学 博士  

工作经历：

2007年4月-2008年8月   和记黄埔医药(上海)有限公司 助理研究员

2011年6月-2013年3月   美国普渡大学  博士后

2013年4月-2016年3月   美国密歇根大学  博士后

2016年3月-至今        中国科学院上海药物研究所  副所长      化学药物研究中心课题组长 研究员

2020年4月-至今        国科大杭州高等研究院 药物科学与技术学院药物化学中心主任     教授工作室首席教授

研究方向：

主要从事药物化学领域研究工作

主要研究方向为基于新靶标的创新药物发现与优化研究，通过运用药物化学、药物合成设计、化学生物学等多学科交叉手段，开展基于表观遗传修饰酶和蛋白-蛋白相互作用等难成药靶点的新药研发。

1、高效合成与先导药物发现技术研究；

2.、基于结构的合理药物设计与成药性优化研究；

3、靶向蛋白降解技术研究；

4、基于天然产物的靶标发现、构效关系以及药物研发。

代表性研究成果：

迄今为止，以通讯或第一作者在 J. Am. Chem. Soc.;Angew. Chem. Int. Ed.; Cancer Res.; J. Med. Chem.; ACS Catal.; Acta Pharm. Sin. B;等国际学术期刊共发表文章 70 余篇，影响因子共计超过500，总引用次数共计超过4000次。作为核心发明人申请国内外专利 30 余项，授权国内外发明专利 17项（第一发明人）。4项专利已实现转化。先后入选中组部“国家海外高层次人才引进青年人才”，“上海市青年科技启明星”，“上海市优秀学术带头人”，“ 山东省泰山学者青年专家”，浦东新区“明珠菁英人才”。

代表性论著如下：

1. 1.Liuyu Hu,^# Yipei Gu,^# Ju Liang, Mengmeng Ning, Junli Yang, Yi Zhang, Hui Qu, Yaxi Yang,* Ying Leng,* and Bing Zhou,* Discovery of Highly Potent and Selective Thyroid Hormone Receptor β Agonists for the Treatment of Nonalcoholic Steatohepatitis. J. Med. Chem.,2023，66, 3284-3300

2. 2.Chao Chen ¹, Tian Lu¹, Panyu Chen¹ , Zizhou Li¹, Yaxi Yang , Shijie Fan, Yuanyuan Zhang, Kaixian Chen,Wei Fu,* Yugang Wang,* Cheng Luo, Bing Zhou*,Cyclization strategy leads to highly potent Bromodomain and extra-terminal (BET) Bromodomain inhibitors for the treatment of acute liver injury. Eur. J. Med. Chem.,2023, 247，115023

3. 3.Yuan Pei^#, Jingfeng Fu^#, Yunkai Shi^#, Mengmeng Zhang, Guanghao Luo, Xiaomin Luo, Ning Song, Tian Mi, Yaxi Yang, Jia Li,* Yubo Zhou,* Bing Zhou*， Discovery of a Potent and Selective Degrader for USP7, Angew. Chem. Int. Ed., 2022, 61, e202204395

4. 4.Xiangbo Yang^#, Huimin Lu^#, Hang Xie^#, Binbin Zhang, Tianqing Nie, Chen Fan, Tao Yang, Yechun Xu, Haixia Su,* Wei Tang,* and Bing Zhou*. Potent and Selective RIPK1 Inhibitors Targeting Dual-Pockets for the Treatment of Systemic Inflammatory Response Syndrome and Sepsis. Angew. Chem. Int. Ed., 2022, 61, e202114922

5. 5.Liping Liao^y , Wenzhen Dang^y , Tingting Lin^y , Jinghua Yu , Tonghai Liu, Wen Li , Senhao Xiao , Lei Feng , Jing Huang, Rong Fu , Jiacheng Li, Liping Liu, Mingchen Wang, Hongru Tao , Hualiang Jiang, Kaixian Chen, Xingxing Diao, Bing Zhou*, Xiaoyan Shen*, Cheng Luo, *A potent PGK1 antagonist reveals PGK1 regulates the production of IL-1β and IL-6. Acta. Pharm. Sin. B., 2022，12(11),4180-4192

6. 6.Qilong Tan^#, Ziqun Liu^#, Xiaobo Gao^#, Yibo Wang^#, Xuefeng Qiu, Jiahui Chen , Liuchun Liang , Hongqian Guo , Shengsong Huang, Denglong Wu , Bing Zhou*, Ronggui Hu* and Zhenfei Li *.Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.Oncogene,2022, 41,4754–4767

7. 7.Jing Niu^#, Hudagula Bai ^#, Zizhou Li, Yuzhe Gao, Yan Zhang, Xiyuan Wang,Yaxi Yang, Yungen Xu,* Meiyu Geng, Zuoquan Xie,* Bing Zhou,* Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration, Eur. J. Med. Chem., 2022, 238, 114482  

8. 8.Wenwen Yu¹, Chao Chen¹, Lei Feng, Tianqi Xia, Chen Shi, Yaxi Yang*, and Bing Zhou*,Rhodium(III)-Catalyzed Asymmetric 1,2-Carboamidation of Alkenes Enables Access to Chiral 2,3-Dihydro-3-benzofuranmethanamides. Org. Lett. 2022, 24, 1762−1767

9. 9.Shijie Fan^#, Liyan Yue^#, Wei Wan^#, Yuanyuan Zhang^#, Bidong Zhang^#, Chinatsu Otomo, Quanfu Li, Tingting Lin, Junchi Hu, Pan Xu, Mingrui Zhu, Hongru Tao, Zhifeng Chen, Lianchun Li, Hong Ding, Zhiyi Yao, Junyan Lu, Yi Wen, Naixia Zhang, Minjia Tan, Kaixian Chen, Yuli Xie, Takanori Otomo, Bing Zhou*, Hualiang Jiang*, Yongjun Dang*, and Cheng Luo*. Inhibition of autophagy by a small molecule through covalent modification of LC3 Protein,Angew. Chem. Int. Ed. 2021, 60, 26105-26114.

10. 10.Tian Lu^#, Yong Li^#, Wenchao Lu^#, TWGM Spitters^#, Xueyu Fang, Jun Wang, Simian Cai, Jing Gao, Yanting Zhou, Zhe Duan, Huan Xiong, Liping Liu, Qi Li, Hualiang Jiang, Kaixian Chen, Hu Zhou, Hua Lin, Huijin Feng, Bing Zhou*, Christopher L. Antos*, Cheng Luo*. Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3. Acta. Pharm. Sin. B., 2021, 11 (10), 3206-3219

11. 11.Xiangbo Yang^#, Zhijia Wang^#, Yuan Pei, Ning Song, Lei Xu, Bo Feng, Hanlin Wang, Xiaomin Luo, Xiaobei Hu, Xiaohui Qiu, Huijin Feng, Yaxi Yang, Yubo Zhou*, Jia Li*, Bing Zhou*. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders. Eur. J. Med. Chem. 2021, 218, 113341

12. 12.Yaxi Yang, Rukang Zhang, Zhaojun Li, Lianghe Mei, Shili Wan, Hong Ding, Zhifeng Chen, Jing Xing, Huijin Feng, Jie Han, Hualiang Jiang, Mingyue Zheng,*Cheng Luo,* Bing Zhou.* Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors. J. Med. Chem. 2020, 63, 1337-1360

13. 13.Chao Chen^#, Shi Chen^#, Yaxi Yang, Bing Zhou.* Rh(III)-catalyzed tandem annulative redox-neutral arylation/amidation of aromatic tethered alkenes. Chem. Sci., 2020, 11, 12124-12129

14. 14.Zizhou Li, Senhao Xiao, Yaxi Yang, Chao Chen, Tian Lu, Zhifeng Chen, Hualiang Jiang, Shijie Chen, Cheng Luo,* and Bing Zhou.* Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-terminal (BET) Bromodomain Inhibitors. J. Med. Chem., 2020, 63, 8, 3956-3975

15. 15.Yunxiang Wu, Zhaoqiang Chen, Yaxi Yang, Weiliang Zhu,* Bing Zhou.* Rh(III)-Catalyzed Redox-Neutral Unsymmetrical C-H Alkylation and Amidation Reactions of N-Phenoxyacetamides. J. Am. Chem. Soc., 2018, 140, 42-45.

16. 16.Bing Zhou^∇, Jiantao Hu^∇, Fuming Xu^∇, Zhuo Chen^∇, Longchuan Bai^∇, Ester Fernandez-Salas^∇, Mei Lin^∇, Liu Liu, Chao-Yie Yang, Yujun Zhao, Donna McEachern, Sally Przybranowski, Bo Wen, Duxin Sun, and Shaomeng Wang*  Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression J. Med. Chem. 2018, 61, 462-481.

17. 17.Longchuan Bai,^# Bing Zhou,^# Chao-Yie Yang, Jiao Ji, Donna McEachern, Sally Przybranowski, Hui Jiang, Jiantao Hu, Fuming Xu, Yujun Zhao, Liu Liu, Ester Fernandez-Salas, Jing Xu, Yali Dou, Bo Wen, Duxin Sun, Jennifer Meagher, Jeanne Stuckey, Daniel F. Hayes, Shunqiang Li, Matthew J. Ellis and Shaomeng Wang.* Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. Cancer Res. 2017, 77（9）, 2476-2487.

18.  

19. 18.Yunxiang Wu, Bing Zhou*. Ruthenium-Catalyzed Direct Hydroxymethylation of Aryl C–H Bonds. ACS Catal., 2017, 7, 2213-2217.

20.  

21. 19.Yaxi Yang, Xuan Wang, Yuanchao Li, and Bing Zhou* A [4+1] Cyclative Capture Approach to 3H-Indole-N-oxides at Room Temperature by Rhodium(III)-Catalyzed C-H Activation. Angew. Chem. Int. Ed. 2015, 54,15400-15404

22. 20.Bing Zhou,* Zhaoqiang Chen, Yaxi Yang,* Wen Ai, Huanyu Tang, Yunxiang Wu, Weiliang Zhu,* Yuanchao Li. Rhodium-Catalyzed Redox-Neutral C-H Functionalization of Arylamine N-Oxides with Diazo Compounds: Primary C(sp³)-H/C(sp²)-H Activation and Oxygen Atom Transfer. Angew. Chem. Int. Ed. 2015, 54, 12121-12126.

科研项目：

主持国家自然科学青年、面上基金、“十三五”国家科技重大专项子课题、中国科学院战略性先导科技专项（A类）、山东省自然科学“杰青”基金等项目。